September 9, 2017 05:49 AM EDT

#ESMO17: AstraZeneca salves stinging setback with a big win in a blockbuster segment of the lung cancer market

MADRID — Just weeks after AstraZeneca was hammered by a round-one failure for its checkpoint combo on non-small cell lung cancer, the pharma giant …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#ES­MO17: As­traZeneca salves sting­ing set­back with a big win in a block­buster seg­ment of the lung can­cer mar­ket